Andrea Finlay to Naltrexone
This is a "connection" page, showing publications Andrea Finlay has written about Naltrexone.
Connection Strength
0.694
-
Finlay AK, Wong JJ, Ellerbe LS, Rubinsky A, Gupta S, Bowe TR, Schmidt EM, Timko C, Burden JL, Harris AHS. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs. J Stud Alcohol Drugs. 2018 11; 79(6):909-917.
Score: 0.148
-
Finlay AK, Binswanger IA, Timko C, Smelson D, Stimmel MA, Yu M, Bowe T, Harris AHS. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science. J Subst Abuse Treat. 2018 12; 95:43-47.
Score: 0.147
-
Finlay AK, Ellerbe LS, Wong JJ, Timko C, Rubinsky AD, Gupta S, Bowe TR, Burden JL, Harris AHS. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. J Subst Abuse Treat. 2017 06; 77:38-43.
Score: 0.132
-
Finlay AK, Harris AH, Rosenthal J, Blue-Howells J, Clark S, McGuire J, Timko C, Frayne SM, Smelson D, Oliva E, Binswanger I. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients. Drug Alcohol Depend. 2016 Mar 01; 160:222-6.
Score: 0.122
-
Harris AH, Bowe T, Del Re AC, Finlay AK, Oliva E, Myrick HL, Rubinsky AD. Extended release naltrexone for alcohol use disorders: quasi-experimental effects on mortality and subsequent detoxification episodes. Alcohol Clin Exp Res. 2015 Jan; 39(1):79-83.
Score: 0.113
-
Harris AH, Bowe T, Hagedorn H, Nevedal A, Finlay AK, Gidwani R, Rosen C, Kay C, Christopher M. Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness. Addict Sci Clin Pract. 2016 09 15; 11(1):15.
Score: 0.032